retatrutide clinical trial results 2024 2025 press release Retatrutide—A Game Changer in Obesity Pharmacotherapy 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”
Description
The following search terms were used: (exenatide OR liraglutide OR albiglutide OR dulaglutide OR lixisenatide OR semaglutide OR tirzepatide OR GLP-1 RAs OR Glucagon-like peptide-1 receptor agonist) AND (acute pancreatitis) AND (case report OR case series)
The severity and duration of these side effects vary considerably between individuals
Oral formulations deserve particular attention
Lead study author, Hamlet Gasoyan, DS, PhD, MPH, a researcher with Cleveland Clinics Center for Value-Based Care Research, spoke to Medical News Today , emphasizing the importance of these results in a real-world setting: Randomized clinical trials documented that discontinuation of novel obesity medications generally leads patients to regain weight, Gasoyan told us
Who should choose MeAgain vs WeightWatchers GLP-1
And the cardiometabolic benefits were equally impressive
